Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Sanyou Bio
Sanyou Biopharmaceuticals is a leading international CRO company that focuses on R&D and services to create innovative antibody drugs.
Sector
Subsector
Keywords
Location
total rounds
Biointron
Biointron is a leading provider of high-quality and cost-effective recombinant protein/antibody reagents.
Sector
Subsector
Keywords
Location
total rounds
total raised
AbTis
AbTis is a biotechnology company that specializes in antibody-drug conjugation technology and solubilization of drugs.
Sector
Subsector
Keywords
Location
total rounds
total raised
Abcore
Abcore is a biotech company that specializes in custom polyclonal antibody services.
Sector
Subsector
Location
Financials
Funding Rounds8
Number of Funding Rounds
Money Raised
Their latest funding was raised on 28.04.2023. Their latest investor Wille AG. Their latest round Grant
InnoSuisse
Innosuisse is the Swiss Innovation Agency promoting science-based innovation for industry and society in Switzerland.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Samsung Ventures
Samsung Venture Investment Corporation (SVIC) is a global venture capital firm that invests in emerging technology startups.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
4BIO Capital
4BIO Ventures is a London-based firm investing in venture capital and public equities in life sciences.
Sector
Subsector
Location
count Of Investments
Pureos Bioventures
Pureos Bioventures is a venture capital fund based in Zurich that exclusively invests in private innovative drug development companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors12
Number of lead investors
Number of investors
Wille AG
Wille AG
Location
count Of Investments
count Of Exists
Damir Jacob Illich
board observer
InnoSuisse
Innosuisse is the Swiss Innovation Agency promoting science-based innovation for industry and society in Switzerland.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Samsung Ventures
Samsung Venture Investment Corporation (SVIC) is a global venture capital firm that invests in emerging technology startups.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
John Rim
John Rim is the Chief Executive Officer and President at Samsung Biologics. John Rim attended Stanford University.
current job
People
Founders3
Dragan Grabulovski
Dragan received his Master’s degree and PhD in Pharmaceutical Sciences from ETH Zürich. From 2007 to 2014 he was co-founder and CSO of Covagen, a Swiss biotech company acquired in 2014 by an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. He was instrumental in Covagen’s trade sale to Johnson & Johnson, in establishing deals with Roche and Mitsubishi Tanabe and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014. Since 2015 he is a serial entrepreneur and Biotech consultant at Grabulovski Consulting Services.
current job
organization founded
Dragan Grabulovski
Philipp Spycher
As the inventor of the Araris Linker Technology, Philipp has a profound background in Bioconjugation and ADCs. He obtained his Master’s Degree and PhD from ETH Zurich at the interface of Material Science and Protein Engineering. During his post-doctoral work at PSI, he introduced the novel approach using transglutaminases for antibody conjugation that led to the discovery of the Araris Linker Technology.
current job
organization founded
Philipp Spycher
Isabella Attinger-Toller
Isabella holds a Master’s Degree in Molecular Biology from University of Basel and obtained a PhD in Tumorimmunology from University of Zurich (UZH). Before joining Araris, she served as Director Pharmacology at Covagen, a Swiss Biotech that was acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical companies of Johnson & Johnson. She was in charge of the pharmacological characterization of various FynomAbs during pre-clinical development that entered clinical testing.
current job
organization founded
Isabella Attinger-Toller
Employee Profiles4
Isabella Attinger-Toller
Co-founder and VP Translational Research